|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...1415161718192021222324...4041» |
- Trial primary completion date: Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=10, Recruiting, Sponsor: Queen Margaret University
Trial primary completion date: Mar 2014 --> Mar 2015
- Trial primary completion date: MSPi: Mindfulness Meditation for Subjects With Severe Speech and Physical Impairments (clinicaltrials.gov) - Oct 22, 2014
P2, N=10, Active, not recruiting, Sponsor: Oregon Health and Science University
Trial primary completion date: Mar 2014 --> Mar 2015 Trial primary completion date: Aug 2014 --> Aug 2020
- methylphenidate tablet / Generic mfg.
Trial primary completion date: Methylphenidate to Improve Balance and Walking in MS (clinicaltrials.gov) - Oct 22, 2014
P2/3, N=24, Recruiting, Sponsor: Oregon Health and Science University
Trial primary completion date: Aug 2014 --> Aug 2020 Trial primary completion date: Jul 2014 --> Jul 2015
- telbermin (sNN-0029) / Newron
New P1 trial: A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS (clinicaltrials.gov) - Oct 22, 2014
P1, N=18, Not yet recruiting, Sponsor: Newron Sweden AB
- | Plegridy (PEG-interferon ?-1a) / Biogen
New P1 trial: Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif (clinicaltrials.gov) - Oct 22, 2014
P1, N=30, Not yet recruiting, Sponsor: Biogen Idec
- || plovamer (CO-14) / EMD Serono
Enrollment status: EMR200575-001: Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) (clinicaltrials.gov) - Oct 21, 2014
P2, N=550, Recruiting, Sponsor: EMD Serono
Trial primary completion date: Jul 2014 --> Jul 2015 Recruiting --> Recruiting
- Trial completion: FlexToBa for People With Multiple Sclerosis (clinicaltrials.gov) - Oct 20, 2014
P1, N=50, Completed, Sponsor: University of Illinois at Urbana-Champaign
Recruiting --> Recruiting Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Trial completion: Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex (clinicaltrials.gov) - Oct 20, 2014
P1/2, N=28, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS (clinicaltrials.gov) - Oct 17, 2014
P2, N=12, Recruiting, Sponsor: University of Manitoba
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2015
- Enrollment open: EMR200109_635: Vitamin D3 and the Stress-axis in MS (clinicaltrials.gov) - Oct 17, 2014
P2, N=80, Recruiting, Sponsor: Academic MS Center Limburg
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Oct 17, 2014
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2014 --> Mar 2015
- Clinical: Autologous SCT for Progressive Systemic Sclerosis: a Prospective NIS Study (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=50, Recruiting, Sponsor: European Group for Blood and Marrow Transplantation
- |||| GSK239512 / GSK
Trial completion: Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 15, 2014
P2, N=131, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Mar 2014 --> Mar 2015 Active, not recruiting --> Completed
- sirolimus / Generic mfg.
Trial primary completion date: Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream (clinicaltrials.gov) - Oct 15, 2014
P1, N=15, Recruiting, Sponsor: Le Bonheur Children's Hospital
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2015
- Clinical: Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled Trial (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=17, Completed, Sponsor: Hasselt University
- Trial completion: Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled Trial (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=17, Completed, Sponsor: Hasselt University
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Completed
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Oct 11, 2014
P1, N=54, Recruiting, Sponsor: BBB-Therapeutics B.V.
Not yet recruiting --> Completed Trial primary completion date: Sep 2014 --> Dec 2014
- || ZB-168 / Zura Bio
Trial initiation date: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Oct 11, 2014
P1, N=60, Recruiting, Sponsor: Pfizer
Trial primary completion date: Sep 2014 --> Dec 2014 Initiation date: Jun 2014 --> Sep 2014
- Enrollment change, Trial withdrawal, HEOR, Cost effectiveness: Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=0, Withdrawn, Sponsor: Department of Veterans Affairs
Initiation date: Jun 2014 --> Sep 2014 N=20 --> 0 | Terminated --> Withdrawn
- || Trial primary completion date: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Oct 10, 2014
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
N=20 --> 0 | Terminated --> Withdrawn Trial primary completion date: Jul 2015 --> Jan 2016
- || Zinbryta (daclizumab) / Biogen, AbbVie
Trial primary completion date: SELECTION: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 10, 2014
P2, N=520, Completed, Sponsor: Biogen Idec
Trial primary completion date: Jul 2015 --> Jan 2016 Trial primary completion date: Oct 2012 --> May 2012
- ||||| Uptravi (selexipag) / J&J, Nippon Shinyaku
New P2 trial: Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Oct 10, 2014
P2, N=70, Not yet recruiting, Sponsor: Actelion
- telbermin (sNN-0029) / Newron
Enrollment open, Trial initiation date, Trial primary completion date: A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS (clinicaltrials.gov) - Oct 10, 2014
P1, N=18, Recruiting, Sponsor: NeuroNova AB
Trial primary completion date: Oct 2012 --> May 2012 Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Sep 2014 | Trial primary completion date: Dec 2014 --> Sep 2015
- Enrollment change, Combination therapy: SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Oct 2, 2014
P2, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Sep 2014 | Trial primary completion date: Dec 2014 --> Sep 2015 N=141 --> 30
- ||||| Rebif (human IFN-?-1a) / EMD Serono
New P4 trial: PROCEED: Effectiveness of Rebif (clinicaltrials.gov) - Oct 2, 2014
P4, N=100, Not yet recruiting, Sponsor: Merck KGaA
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P1 trial, P1 data, MRI: A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients (clinicaltrials.gov) - Oct 2, 2014
P1, N=12, Not yet recruiting, Sponsor: Johns Hopkins University
- Avastin (bevacizumab) / Roche
Enrollment closed: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Sep 30, 2014
P1, N=10, Active, not recruiting, Sponsor: Johns Hopkins University
N=141 --> 30 Recruiting --> Active, not recruiting
- || Betaseron (IFN-β-1b) / Bayer
Trial primary completion date, HEOR: BetaSleep: Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=300, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- ||| Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment change, Trial primary completion date, Monotherapy: SELECTED: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 29, 2014
P2, N=410, Active, not recruiting, Sponsor: Biogen Idec
Trial primary completion date: Dec 2015 --> Dec 2016 N=600 --> 410 | Trial primary completion date: May 2015 --> Jan 2018
- |||| vatelizumab (GBR 500) / Glenmark
Enrollment open: Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 29, 2014
P2, N=168, Recruiting, Sponsor: Genzyme, a Sanofi Company
N=600 --> 410 | Trial primary completion date: May 2015 --> Jan 2018 Not yet recruiting --> Recruiting
- |||| Zinbryta (daclizumab) / Biogen, AbbVie
Trial primary completion date: An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 29, 2014
P3, N=133, Active, not recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Apr 2013
- | Trial termination: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (clinicaltrials.gov) - Sep 28, 2014
P4, N=54, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2016 --> Apr 2013 Completed --> Terminated; Due to slow enrollment the study was terminated early
- ||| Betaseron (IFN-β-1b) / Bayer
Adherence: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=450, Not yet recruiting, Sponsor: Bayer
- autologous mesenchymal stem cells / Tianjin Medical University General Hospital
New P2 trial: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov) - Sep 28, 2014
P2, N=15, Recruiting, Sponsor: Tianjin Medical University General Hospital
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, Adherence: Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=735, Completed, Sponsor: Bayer
Completed --> Terminated; Due to slow enrollment the study was terminated early Active, not recruiting --> Completed
- Enrollment open: Consolidation & Interference in Multiple Sclerosis (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=72, Recruiting, Sponsor: Kessler Foundation
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Lemtrada (alemtuzumab) / Sanofi
Clinical: EMERALD: Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (clinicaltrials.gov) - Sep 28, 2014
P4, N=56, Recruiting, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Sativex (nabiximols) / Jazz
P3 data, Trial primary completion date: Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. (clinicaltrials.gov) - Sep 22, 2014
P3, N=711, Not yet recruiting, Sponsor: GW Research Ltd
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Jun 2017
- Clinical: Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Echosense Ltd.
- Clinical: Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Echosense Ltd.
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Trial completion, Enrollment change, Trial primary completion date: Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations (clinicaltrials.gov) - Sep 16, 2014
P4, N=25, Completed, Sponsor: The University of Texas Health Science Center, Houston
Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Completed | N=40 --> 25 | Trial primary completion date: Dec 2013 --> Aug 2014
- ||||| Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: ESCALATE: Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (clinicaltrials.gov) - Sep 16, 2014
P4, N=200, Not yet recruiting, Sponsor: Biogen Idec
- New P1 trial: Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Sep 16, 2014
P1, N=200, Recruiting, Sponsor: Neurogen Brain and Spine Institute
- Plegridy (PEG-interferon β-1a) / Biogen
Enrollment change, Trial withdrawal: Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Sep 15, 2014
P3, N=0, Withdrawn, Sponsor: Johns Hopkins University
Recruiting --> Completed | N=40 --> 25 | Trial primary completion date: Dec 2013 --> Aug 2014 N=120 --> 0 | Recruiting --> Withdrawn
- Enrollment closed, Trial primary completion date: Neuromuscular Ultrasound in ALS (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=50, Active, not recruiting, Sponsor: Duke University
N=120 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jul 2015
- ||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment closed: EMR200136-549: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (clinicaltrials.gov) - Sep 12, 2014
P2, N=80, Active, not recruiting, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jul 2015 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=45, Completed, Sponsor: Sina Hospital, Iran
Recruiting --> Active, not recruiting Recruiting --> Completed | N=30 --> 45
- || ZB-168 / Zura Bio
Trial initiation date: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Sep 11, 2014
P1, N=60, Recruiting, Sponsor: Pfizer
Recruiting --> Completed | N=30 --> 45 Initiation date: Sep 2014 --> Jun 2014
- Clinical: PET Imaging in ALS Patients (clinicaltrials.gov) - Sep 11, 2014
P=N/A, N=38, Recruiting, Sponsor: Johns Hopkins University
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Combination therapy: Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=10, Recruiting, Sponsor: MinYoung Kim, M.D.